Cancer Therapeutics Market by Application (Blood Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Cervical Cancer, Head & Neck Cancer, Glioblastoma, Malignant Meningioma, Mesothelioma, Melanoma, and Others) and Top Selling Drugs (Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar, and Others): Global Opportunity Analysis and Industry Forecast, 2019–2026
The use of targeted, biologic (immunotherapy) & other forms of therapies administered to treat cancer through oncology drugs is known as cancer therapeutics. The global cancer therapeutics market size was valued at $98,900 million in 2018 and is estimated to reach at $180,193 million by 2026, registering a CAGR of 7.7% from 2019 to 2026.
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
Upsurge in collaboration between pharmaceutical companies, rise in cancer awareness & availability of oncology drugs, increase in cancer funding & research, and growth in geriatric population are the key factors that augment the growth of the cancer therapeutics market. Furthermore, rise in prevalence of cancer cases is expected to boost the market growth.
However, adverse effects associated with cancer therapeutics market and high costs associated with oncology drug development are some of the factors that impede the market growth. Conversely, the high potential of emerging economies and increase in demand for personalized medicine is expected to provide new opportunities for the market players in future.
The cancer therapeutics market is segmented based on application, top selling drugs, and region. Based on application, the market is divided into blood cancer, lung cancer, colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and others. By top selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan, Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva, Perjeta, Temodar and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative market analysis from 2018 to 2026 to identify the prevailing opportunities along with strategic assessment of the global cancer therapeutics market.
- Cancer therapeutics market size and market estimations are based on a comprehensive analysis of the applications, top selling drugs, and developments in the industry.
- An in-depth analysis based on region assists to understand the regional market and facilitate the strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.
- By Application
- Blood Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Breast Cancer
- Cervical Cancer
- Head and Neck Cancer
- Glioblastoma
- Malignant Meningioma
- Mesothelioma
- Melanoma
- Others
- By Top Selling Drugs
- Revlimid
- Avastin
- Herceptin
- Rituxan
- Opdivo
- Gleevec
- Velcade
- Imbruvica
- Ibrance
- Zytiga
- Alimta
- Xtandi
- Tarceva
- Perjeta
- Temodar
- Others
- By Region
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Taiwan
- Rest of Asia-Pacific
- LAMEA
- Latin America
- Middle-East
- Africa
- F. Hoffmann-La Roche AG
- Bristol-Myers Squibb Company
- AbbVie, Inc.
- Johnson & Johnson
- Celgene Corporation
- Astellas Pharma, Inc.
- Pfizer, Inc.
- Novartis AG
- Merck KGaA
- Eli Lilly and Company
- AstraZeneca plc
- Bayer AG
- Takeda Pharmaceutical Company Limited
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Market share analysis, 2018
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions & collaborations
3.6.2. Restraints
3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy
3.6.3. Opportunities
3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economies
CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Blood cancer
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Lung cancer
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Breast cancer
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Colorectal cancer
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Prostate cancer
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Cervical cancer
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Head & neck cancer
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. Glioblastoma
4.9.1. Key market trends, growth factors, and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country
4.10. Malignant meningioma
4.10.1. Key market trends, growth factors, and opportunities
4.10.2. Market size and forecast, by region
4.10.3. Market analysis, by country
4.11. Mesothelioma
4.11.1. Key market trends, growth factors, and opportunities
4.11.2. Market size and forecast, by region
4.11.3. Market analysis, by country
4.12. Melanoma
4.12.1. Key market trends, growth factors, and opportunities
4.12.2. Market size and forecast, by region
4.12.3. Market analysis, by country
4.13. Others
4.13.1. Key market trends, growth factors, and opportunities
4.13.2. Market size and forecast, by region
4.13.3. Market analysis, by country
CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS
5.1. Overview
5.1.1. Market size and forecast
5.2. Revlimid
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region
5.3. Avastin
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region
5.4. Herceptin
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region
5.5. Rituxan
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region
5.6. Opdivo
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region
5.7. Gleevec
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region
5.8. Velcade
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region
5.9. Imbruvica
5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region
5.10. Ibrance
5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region
5.11. Zytiga
5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region
5.12. Alimta
5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region
5.13. Xtandi
5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region
5.14. Tarceva
5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region
5.15. Perjeta
5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region
5.16. Temodar
5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region
5.17. Other drugs
5.17.1. Market size and forecast, by region
5.17.2. Market analysis, by region
CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by application
6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe cancer therapeutics market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by application
6.4.2.4. Taiwan
6.4.2.4.1. Taiwan market size and forecast, by application
6.4.2.5. South Korea
6.4.2.5.1. South Korea market size and forecast, by application
6.4.2.6. Australia
6.4.2.6.1. Australia market size and forecast, by application
6.4.2.7. Rest of Asia-Pacific
6.4.2.7.1. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Bristol Myers Squibb Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Celgene Corporation
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Eli Lilly and Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. F. Hoffmann-La Roche Ltd.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. EleInformatiBusiness performance
7.6.6. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Merck & Co., Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. KEY FINDINGS OF THE STUDY
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Market share analysis, 2018
3.4. Porters five forces analysis
3.5. Clinical trials
3.6. Market dynamics
3.6.1. Drivers
3.6.1.1. Increase in prevalence of cancer
3.6.1.2. Surge in cancer research
3.6.1.3. Rise in strategic acquisitions & collaborations
3.6.2. Restraints
3.6.2.1. High cost of drug development and threat of failure
3.6.2.2. Adverse effects associated with cancer drug therapy
3.6.3. Opportunities
3.6.3.1. High potential associated with personalized medicines
3.6.3.2. Increase in purchasing power of emerging economies
CHAPTER 4: CANCER THERAPEUTICS MARKET, APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Blood cancer
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Lung cancer
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Breast cancer
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Colorectal cancer
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Prostate cancer
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Cervical cancer
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country
4.8. Head & neck cancer
4.8.1. Key market trends, growth factors, and opportunities
4.8.2. Market size and forecast, by region
4.8.3. Market analysis, by country
4.9. Glioblastoma
4.9.1. Key market trends, growth factors, and opportunities
4.9.2. Market size and forecast, by region
4.9.3. Market analysis, by country
4.10. Malignant meningioma
4.10.1. Key market trends, growth factors, and opportunities
4.10.2. Market size and forecast, by region
4.10.3. Market analysis, by country
4.11. Mesothelioma
4.11.1. Key market trends, growth factors, and opportunities
4.11.2. Market size and forecast, by region
4.11.3. Market analysis, by country
4.12. Melanoma
4.12.1. Key market trends, growth factors, and opportunities
4.12.2. Market size and forecast, by region
4.12.3. Market analysis, by country
4.13. Others
4.13.1. Key market trends, growth factors, and opportunities
4.13.2. Market size and forecast, by region
4.13.3. Market analysis, by country
CHAPTER 5: CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS
5.1. Overview
5.1.1. Market size and forecast
5.2. Revlimid
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by region
5.3. Avastin
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by region
5.4. Herceptin
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by region
5.5. Rituxan
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by region
5.6. Opdivo
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by region
5.7. Gleevec
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by region
5.8. Velcade
5.8.1. Market size and forecast, by region
5.8.2. Market analysis, by region
5.9. Imbruvica
5.9.1. Market size and forecast, by region
5.9.2. Market analysis, by region
5.10. Ibrance
5.10.1. Market size and forecast, by region
5.10.2. Market analysis, by region
5.11. Zytiga
5.11.1. Market size and forecast, by region
5.11.2. Market analysis, by region
5.12. Alimta
5.12.1. Market size and forecast, by region
5.12.2. Market analysis, by region
5.13. Xtandi
5.13.1. Market size and forecast, by region
5.13.2. Market analysis, by region
5.14. Tarceva
5.14.1. Market size and forecast, by region
5.14.2. Market analysis, by region
5.15. Perjeta
5.15.1. Market size and forecast, by region
5.15.2. Market analysis, by region
5.16. Temodar
5.16.1. Market size and forecast, by region
5.16.2. Market analysis, by region
5.17. Other drugs
5.17.1. Market size and forecast, by region
5.17.2. Market analysis, by region
CHAPTER 6: CANCER THERAPEUTICS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends, growth factors, and opportunities
6.2.2. North America market size and forecast, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by application
6.2.3. North America market size and forecast, by application
6.2.4. North America market size and forecast, by top selling drugs
6.3. Europe
6.3.1. Key market trends, growth factors, and opportunities
6.3.2. Europe cancer therapeutics market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by application
6.3.4. Europe market size and forecast, by top selling drugs
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors, and opportunities
6.4.2. Asia-Pacific market size and forecast, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by application
6.4.2.4. Taiwan
6.4.2.4.1. Taiwan market size and forecast, by application
6.4.2.5. South Korea
6.4.2.5.1. South Korea market size and forecast, by application
6.4.2.6. Australia
6.4.2.6.1. Australia market size and forecast, by application
6.4.2.7. Rest of Asia-Pacific
6.4.2.7.1. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by application
6.4.4. Asia-Pacific market size and forecast, by top selling drugs
6.5. LAMEA
6.5.1. Key market trends, growth factors, and opportunities
6.5.2. LAMEA market size and forecast, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by application
6.5.4. LAMEA market size and forecast, by top selling drugs
CHAPTER 7: COMPANY PROFILES
7.1. AbbVie Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Astellas Pharma Inc.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.2.6. Key strategic moves and developments
7.3. Bristol Myers Squibb Company
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.3.6. Key strategic moves and developments
7.4. Celgene Corporation
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.4.6. Key strategic moves and developments
7.5. Eli Lilly and Company
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.5.6. Key strategic moves and developments
7.6. F. Hoffmann-La Roche Ltd.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. EleInformatiBusiness performance
7.6.6. Key strategic moves and developments
7.7. Johnson & Johnson
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.7.6. Key strategic moves and developments
7.8. Merck & Co., Inc.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.8.6. Key strategic moves and developments
7.9. Novartis AG
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.9.6. Key strategic moves and developments
7.10. Pfizer Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. COMPLETED CLINICAL TRIALS IN CANCER THERAPEUTICS MARKET
TABLE 02. GLOBAL CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 03. BLOOD CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BREAST CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. COLORECTAL CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. PROSTATE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. CERVICAL CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. HEAD & NECK CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 10. GLIOBLASTOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 11. MALIGNANT MENINGIOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 12. MESOTHELIOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 13. MELANOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 14. OTHER CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 15. GLOBAL CANCER THERAPEUTICS MARKET REVENUE, BY TOP SELLING DRUGS, 2018–2026 ($MILLION)
TABLE 16. REVLIMID CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 17. AVASTIN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 18. HERCEPTIN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 19. RITUXAN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 20. OPDIVO CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 21. GLEEVEC CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 22. VELCADE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 23. IMBRUVICA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 24. IBRANCE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 25. ZYTIGA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 26. ALIMTA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 27. XTANDI CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 28. TARCEVA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 29. PERJETA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 30. TEMODAR CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 31. CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 32. CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 33. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 34. U.S. CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 35. CANADA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 37. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 38. EUROPE CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 39. GERMANY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 40. FRANCE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 41. UK CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 42. ITALY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 43. SPAIN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 44. REST OF EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 45. EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 46. EUROPE CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 47. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 48. JAPAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 49. CHINA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 50. INDIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 51. TAIWAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 52. SOUTH KOREA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 53. AUSTRALIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 54. REST OF ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 55. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 56. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 57. LAMEA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 58. LATIN AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 59. MIDDLE EAST CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 60. AFRICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 61. LAMEA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 62. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 63. ABBVIE: COMPANY SNAPSHOT
TABLE 64. ABBVIE: OPERATING SEGMENTS
TABLE 65. ABBVIE: PRODUCT PORTFOLIO
TABLE 66. ASTELLAS: COMPANY SNAPSHOT
TABLE 67. ASTELLAS: PRODUCT PORTFOLIO
TABLE 68. BMS: COMPANY SNAPSHOT
TABLE 69. BMS: OPERATING SEGMENTS
TABLE 70. BMS: PRODUCT PORTFOLIO
TABLE 71. CELGENE: COMPANY SNAPSHOT
TABLE 72. CELGENE: OPERATING SEGMENTS
TABLE 73. CELGENE: PRODUCT PORTFOLIO
TABLE 74. ELI LILLY: COMPANY SNAPSHOT
TABLE 75. ELI LILLY: OPERATING SEGMENTS
TABLE 76. ROCHE: COMPANY SNAPSHOT
TABLE 77. ROCHE: OPERATING SEGMENTS
TABLE 78. ROCHE: PRODUCT PORTFOLIO
TABLE 79. J&J: COMPANY SNAPSHOT
TABLE 80. J&J: OPERATING SEGMENTS
TABLE 81. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 82. MERCK: COMPANY SNAPSHOT
TABLE 83. MERCK: OPERATING SEGMENTS
TABLE 84. MERCK: PRODUCT TYPE PORTFOLIO
TABLE 85. NOVARTIS: COMPANY SNAPSHOT
TABLE 86. NOVARTIS: OPERATING SEGMENTS
TABLE 87. NOVARTIS: PRODUCT PORTFOLIO
TABLE 88. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
TABLE 89. PFIZER: COMPANY SNAPSHOT
TABLE 90. PFIZER: OPERATING SEGMENTS
TABLE 91. PFIZER: PRODUCT PORTFOLIO
TABLE 01. COMPLETED CLINICAL TRIALS IN CANCER THERAPEUTICS MARKET
TABLE 02. GLOBAL CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 03. BLOOD CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. LUNG CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. BREAST CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. COLORECTAL CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 07. PROSTATE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. CERVICAL CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. HEAD & NECK CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 10. GLIOBLASTOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 11. MALIGNANT MENINGIOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 12. MESOTHELIOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 13. MELANOMA CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 14. OTHER CANCER THERAPEUTICS MARKET, BY REGION, 2019–2026 ($MILLION)
TABLE 15. GLOBAL CANCER THERAPEUTICS MARKET REVENUE, BY TOP SELLING DRUGS, 2018–2026 ($MILLION)
TABLE 16. REVLIMID CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 17. AVASTIN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 18. HERCEPTIN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 19. RITUXAN CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 20. OPDIVO CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 21. GLEEVEC CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 22. VELCADE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 23. IMBRUVICA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 24. IBRANCE CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 25. ZYTIGA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 26. ALIMTA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 27. XTANDI CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 28. TARCEVA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 29. PERJETA CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 30. TEMODAR CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 31. CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, BY REGION, 2018–2026 ($MILLION)
TABLE 32. CANCER THERAPEUTICS MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 33. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 34. U.S. CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 35. CANADA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 36. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 37. NORTH AMERICA CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 38. EUROPE CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 39. GERMANY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 40. FRANCE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 41. UK CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 42. ITALY CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 43. SPAIN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 44. REST OF EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 45. EUROPE CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 46. EUROPE CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 47. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 48. JAPAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 49. CHINA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 50. INDIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 51. TAIWAN CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 52. SOUTH KOREA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 53. AUSTRALIA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 54. REST OF ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 55. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 56. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 57. LAMEA CANCER THERAPEUTICS MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE 58. LATIN AMERICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 59. MIDDLE EAST CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 60. AFRICA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 61. LAMEA CANCER THERAPEUTICS MARKET, BY APPLICATION, 2018–2026 ($MILLION)
TABLE 62. ASIA-PACIFIC CANCER THERAPEUTICS MARKET, BY TOP SELLING DRUGS, 2018-2026 ($MILLION)
TABLE 63. ABBVIE: COMPANY SNAPSHOT
TABLE 64. ABBVIE: OPERATING SEGMENTS
TABLE 65. ABBVIE: PRODUCT PORTFOLIO
TABLE 66. ASTELLAS: COMPANY SNAPSHOT
TABLE 67. ASTELLAS: PRODUCT PORTFOLIO
TABLE 68. BMS: COMPANY SNAPSHOT
TABLE 69. BMS: OPERATING SEGMENTS
TABLE 70. BMS: PRODUCT PORTFOLIO
TABLE 71. CELGENE: COMPANY SNAPSHOT
TABLE 72. CELGENE: OPERATING SEGMENTS
TABLE 73. CELGENE: PRODUCT PORTFOLIO
TABLE 74. ELI LILLY: COMPANY SNAPSHOT
TABLE 75. ELI LILLY: OPERATING SEGMENTS
TABLE 76. ROCHE: COMPANY SNAPSHOT
TABLE 77. ROCHE: OPERATING SEGMENTS
TABLE 78. ROCHE: PRODUCT PORTFOLIO
TABLE 79. J&J: COMPANY SNAPSHOT
TABLE 80. J&J: OPERATING SEGMENTS
TABLE 81. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
TABLE 82. MERCK: COMPANY SNAPSHOT
TABLE 83. MERCK: OPERATING SEGMENTS
TABLE 84. MERCK: PRODUCT TYPE PORTFOLIO
TABLE 85. NOVARTIS: COMPANY SNAPSHOT
TABLE 86. NOVARTIS: OPERATING SEGMENTS
TABLE 87. NOVARTIS: PRODUCT PORTFOLIO
TABLE 88. NOVARTIS: NET SALES, 2016–2018 ($MILLION)
TABLE 89. PFIZER: COMPANY SNAPSHOT
TABLE 90. PFIZER: OPERATING SEGMENTS
TABLE 91. PFIZER: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL CANCER THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016–2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2018*
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016–2018*
FIGURE 06. MARKET SHARE ANALYSIS, 2016
FIGURE 07. LOW BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09. LOW THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE THREAT OF SUBSTITUTION
FIGURE 11. HIGH COMPETITIVE RIVALRY
FIGURE 12. CANCER THERAPEUTICS MARKET: IMPACT ANALYSIS
FIGURE 13. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (MEN)
FIGURE 14. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (WOMEN)
FIGURE 15. COMPARATIVE COUNTRY ANALYSIS OF BLOOD CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 16. COMPARATIVE COUNTRY ANALYSIS OF LUNG CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 17. COMPARATIVE COUNTRY ANALYSIS OF BREAST CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 18. COMPARATIVE COUNTRY ANALYSIS OF COLORECTAL CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 19. COMPARATIVE COUNTRY ANALYSIS OF PROSTATE CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 20. COMPARATIVE COUNTRY ANALYSIS OF CERVICAL CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 21. COMPARATIVE COUNTRY ANALYSIS OF HEAD & NECK CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 22. COMPARATIVE COUNTRY ANALYSIS OF GLIOBLASTOMA CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 23. COMPARATIVE COUNTRY ANALYSIS OF MALIGNANT MENINGIOMA CANCER THERAPEUTICS MARKET , 2018 & 2026 ($MILLION)
FIGURE 24. COMPARATIVE COUNTRY ANALYSIS OF MESOTHELIOMA CANCER THERAPEUTICS, 2018 & 2026 ($MILLION)
FIGURE 25. COMPARATIVE COUNTRY ANALYSIS OF MELANOMA CANCER THERAPEUTICS MARKET , 2018 & 2026 ($MILLION)
FIGURE 26. COMPARATIVE COUNTRY ANALYSIS OF OTHER CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 27. COMPARATIVE REGION ANALYSIS OF REVLIMID CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 28. COMPARATIVE REGION ANALYSIS OF AVASTIN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 29. COMPARATIVE REGION ANALYSIS OF HERCEPTIN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 30. COMPARATIVE REGION ANALYSIS OF RITUXAN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 31. COMPARATIVE REGION ANALYSIS OF OPDIVO CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 32. COMPARATIVE REGION ANALYSIS OF GLEEVEC CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 33. COMPARATIVE REGION ANALYSIS OF VELCADE CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 34. COMPARATIVE REGION ANALYSIS OF IMBRUVICA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 35. COMPARATIVE REGION ANALYSIS OF IBRANCE CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 36. COMPARATIVE REGION ANALYSIS OF ZYTIGA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 37. COMPARATIVE REGION ANALYSIS OF ALIMTA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 38. COMPARATIVE REGION ANALYSIS OF XTANDI CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 39. COMPARATIVE REGION ANALYSIS OF TARCEVA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 40. COMPARATIVE REGION ANALYSIS OF PERJETA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 41. COMPARATIVE REGION ANALYSIS OF CANCER THERAPEUTICS MARKET FOR TEMODAR, 2018 AND 2026 ($MILLION)
FIGURE 42. COMPARATIVE REGION ANALYSIS OF CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, 2018 AND 2026 ($MILLION)
FIGURE 43. ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 44. ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45. ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 46. ASTELLAS: NET SALES, 2016–2018 ($MILLION)
FIGURE 47. ASTELLAS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48. ASTELLAS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 49. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. BMS: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 51. BMS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 52. CELGENE: NET SALES, 2016–2018 ($MILLION)
FIGURE 53. CELGENE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 54. CELGENE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 55. ELI LILLY: NET SALES, 2016–2018 ($MILLION)
FIGURE 56. ELI LILLY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 57. ELI LILLY: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 58. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 59. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 60. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 61. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 62. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 63. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 64. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 65. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 66. MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 67. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 68. NOVARTIS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 69. PFIZER NET SALES, 2016–2018 ($MILLION)
FIGURE 70. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 71. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 01. GLOBAL CANCER THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2016–2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016–2018*
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2016–2018*
FIGURE 06. MARKET SHARE ANALYSIS, 2016
FIGURE 07. LOW BARGAINING POWER OF BUYERS
FIGURE 08. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 09. LOW THREAT OF NEW ENTRANTS
FIGURE 10. MODERATE THREAT OF SUBSTITUTION
FIGURE 11. HIGH COMPETITIVE RIVALRY
FIGURE 12. CANCER THERAPEUTICS MARKET: IMPACT ANALYSIS
FIGURE 13. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (MEN)
FIGURE 14. COMPARISON OF CANCER INCIDENCE PROJECTION (2035) CANCER INCIDENCE OBSERVED (2014) IN THE UK POPULATION (WOMEN)
FIGURE 15. COMPARATIVE COUNTRY ANALYSIS OF BLOOD CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 16. COMPARATIVE COUNTRY ANALYSIS OF LUNG CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 17. COMPARATIVE COUNTRY ANALYSIS OF BREAST CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 18. COMPARATIVE COUNTRY ANALYSIS OF COLORECTAL CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 19. COMPARATIVE COUNTRY ANALYSIS OF PROSTATE CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 20. COMPARATIVE COUNTRY ANALYSIS OF CERVICAL CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 21. COMPARATIVE COUNTRY ANALYSIS OF HEAD & NECK CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 22. COMPARATIVE COUNTRY ANALYSIS OF GLIOBLASTOMA CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 23. COMPARATIVE COUNTRY ANALYSIS OF MALIGNANT MENINGIOMA CANCER THERAPEUTICS MARKET , 2018 & 2026 ($MILLION)
FIGURE 24. COMPARATIVE COUNTRY ANALYSIS OF MESOTHELIOMA CANCER THERAPEUTICS, 2018 & 2026 ($MILLION)
FIGURE 25. COMPARATIVE COUNTRY ANALYSIS OF MELANOMA CANCER THERAPEUTICS MARKET , 2018 & 2026 ($MILLION)
FIGURE 26. COMPARATIVE COUNTRY ANALYSIS OF OTHER CANCER THERAPEUTICS MARKET, 2018 & 2026 ($MILLION)
FIGURE 27. COMPARATIVE REGION ANALYSIS OF REVLIMID CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 28. COMPARATIVE REGION ANALYSIS OF AVASTIN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 29. COMPARATIVE REGION ANALYSIS OF HERCEPTIN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 30. COMPARATIVE REGION ANALYSIS OF RITUXAN CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 31. COMPARATIVE REGION ANALYSIS OF OPDIVO CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 32. COMPARATIVE REGION ANALYSIS OF GLEEVEC CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 33. COMPARATIVE REGION ANALYSIS OF VELCADE CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 34. COMPARATIVE REGION ANALYSIS OF IMBRUVICA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 35. COMPARATIVE REGION ANALYSIS OF IBRANCE CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 36. COMPARATIVE REGION ANALYSIS OF ZYTIGA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 37. COMPARATIVE REGION ANALYSIS OF ALIMTA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 38. COMPARATIVE REGION ANALYSIS OF XTANDI CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 39. COMPARATIVE REGION ANALYSIS OF TARCEVA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 40. COMPARATIVE REGION ANALYSIS OF PERJETA CANCER THERAPEUTICS MARKET, 2018 AND 2026 ($MILLION)
FIGURE 41. COMPARATIVE REGION ANALYSIS OF CANCER THERAPEUTICS MARKET FOR TEMODAR, 2018 AND 2026 ($MILLION)
FIGURE 42. COMPARATIVE REGION ANALYSIS OF CANCER THERAPEUTICS MARKET FOR OTHER DRUGS, 2018 AND 2026 ($MILLION)
FIGURE 43. ABBVIE: NET SALES, 2016–2018 ($MILLION)
FIGURE 44. ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 45. ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 46. ASTELLAS: NET SALES, 2016–2018 ($MILLION)
FIGURE 47. ASTELLAS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 48. ASTELLAS: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 49. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 50. BMS: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 51. BMS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 52. CELGENE: NET SALES, 2016–2018 ($MILLION)
FIGURE 53. CELGENE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 54. CELGENE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 55. ELI LILLY: NET SALES, 2016–2018 ($MILLION)
FIGURE 56. ELI LILLY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 57. ELI LILLY: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 58. ROCHE: NET SALES, 2016–2018 ($MILLION)
FIGURE 59. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 60. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 61. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 62. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 63. J&J: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 64. MERCK: NET SALES, 2016–2018 ($MILLION)
FIGURE 65. MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 66. MERCK: REVENUE SHARE BY REGION, 2018 (%)
FIGURE 67. NOVARTIS: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 68. NOVARTIS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 69. PFIZER NET SALES, 2016–2018 ($MILLION)
FIGURE 70. PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 71. PFIZER: REVENUE SHARE BY REGION, 2018 (%)
